Photonis Launches Two Market-Leading Solutions to Advance Single Photon Detection and Imaging Applications
23.1.2025 09:00:00 CET | ACCESS Newswire | Press release
Advancing Photon Detection and Imaging: Photonis Unveils Cricket™ Pro and PhotonPix™
SAN FRANCISCO, CA / ACCESS Newswire / January 23, 2025 / Photonis, a leading brand of Exosens and global leader in advanced photon detection and imaging solutions, proudly announces the launch of Cricket™ Pro and PhotonPix™. Designed to redefine the possibilities of single photon detection and imaging, these cutting-edge solutions empower researchers and industry professionals to achieve unparalleled performance across applications such as biomedical imaging, quantum science, and high-energy physics.Cricket Pro and PhotonPix
These technologies will officially debut at SPIE Photonics West 2025 in San Francisco, CA.
Cricket™ Pro: Transforming Low-Light Imaging with High-Speed Precision
The Cricket™ Pro brings unprecedented imaging capabilities for low-light and single-photon imaging applications. This innovative, plug-and-play image intensifier adapter easily fits any professional, scientific, F-Mount camera, delivering high resolution and ultra-high-speed functionality for demanding low-light applications. Key features of the Cricket™ Pro include:
Expanded 25 mm active detection area
High-speed gating as fast as 3 nanoseconds
Remarkable 3 MHz Burst or 30kHz repetition rate
Matched with High-performance Photonis Image Intensifier
F-Mount lens/camera interface
Fully integrated power and gating electronics
With these enhancements, Cricket™ Pro sets a new benchmark for scientific imaging, providing precise, rapid, and reliable performance tailored for researchers and industry professionals.
PhotonPix™: Ultra High-Count Rate Module for Single-Photon Detection
Photonis also proudly introduces PhotonPix™, a high-count rate MCP-PMT-based plug-and-play module engineered for ultra-high timing precision single-photon detection. Combining state-of-the-art technology with user-centric design, PhotonPix offers:
An Ø8 mm sensitive area
Extreme-low dark count rate as low as 20 cps
Count rates exceeding 200 MHz in Burst mode, making it ideal for high-demand applications
Timing resolution below 15 ps for unmatched precision
PhotonPix™ is ideal for ultra-fast Single Photon Detection and time-correlated applications such as LIDAR, Photon Entanglement, or Lifetime Imaging. The module's versatility accommodates various high-quantum-efficiency (Hi-QE) photocathodes from Photonis, covering the spectrum range from 150nm to 900nm, making it the perfect fit for researchers and industry professionals.
Experience the Future of Photon Detection and Imaging
Discover how the Cricket™ Pro and PhotonPix™ can transform your research and applications. Visit Photonis at Booth #1827 during SPIE Photonics West 2025 to see live demonstrations and connect with our experts.
ABOUT PHOTONIS:
Photonis is a leading product brand of Exosens, a high-tech company with more than 85 years of experience in the innovation, development, manufacture and sale of high-end electro-optical technologies. Photonis offers its customers photo-detection and low light conditions imaging solutions for extremely demanding environments such as Defense & Security, Nuclear Safety, Life Science and Industrial & Non-Destructive testing. Photonis is internationally recognized as a leading brand and a major innovator in its fields with production and R&D sites in Europe and North America.
Contact Information
Sales Manager
science@exosens.com
+31 50 501 8808
SOURCE: Exosens
View the original press release on ACCESS Newswire
Exosens
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release
OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to
Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release
CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in
CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom